MHRA paediatric investigation plan
NEISSERIA MENINGITIDIS GROUP C POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN (NEISSERIA MENINGITIDIS GROUP C POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN)
MHRA paediatric investigation plan MHRA-100851-PIP01-23 -M01 (update) · Modification
Key facts
| PIP number | MHRA-100851-PIP01-23 -M01 (update) |
|---|---|
| Active substances | NEISSERIA MENINGITIDIS GROUP C POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, NEISSERIA MENINGITIDIS GROUP Y POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN, Recombinant Neisseria meningitidis serogroup B protein 1, Recombinant Neisseria meningitidis serogroup B protein 2, Recombinant Neisseria meningitidis serogroup B Protein-based active substance, Recombinant Neisseria meningitidis serogroup B protein 3 |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of meningococcal disease (serogroups A, B, C, W and Y) |
| Decision | PM: decision on the application for modification of an agreed paediatric investigation plan. |
| Published | Apr 9, 2025 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: